Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on April 29, 2008
JNCI Journal of the National Cancer Institute 2008 100(9):682-683; doi:10.1093/jnci/djn105
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
100/9/682    most recent
djn105v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Millikan, R. E.
Right arrow Articles by Thall, P. F.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Millikan, R. E.
Right arrow Articles by Thall, P. F.
Related Collections
Right arrowRelated Correspondence
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press.

CORRESPONDENCE

Response:Re: Adaptive Therapy for Androgen-Independent Prostate Cancer: A Randomized Selection Trial of Four Regimens

Randall E. Millikan, Christopher J. Logothetis, Peter F. Thall

Affiliation of authors: M. D. Anderson Cancer Center, University of Texas, Houston, TX

Correspondence to: Randall E. Millikan, PhD, MD, University of Texas, M. D. Anderson Cancer Center P.O. Box 301439 Houston, TX 77030 (e-mail: rmillika@mdanderson.org).

The first 10% of the full text of this article appears below.

Armstrong et al. correctly point out that we made no comparison to the accepted standard therapy for symptomatic castration-resistant prostate cancer (namely, docetaxel and prednisone every 3 weeks). The purpose of our study was to evaluate the feasibility of a method for efficiently ranking, by order of clinical efficacy, four regimens widely used at the time that our study was designed. Importantly, we did this by means of a clinically grounded algorithm that also serves . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Correspondence

Re: Adaptive Therapy for Androgen-Independent Prostate Cancer: A Randomized Selection Trial of Four Regimens
Andrew J. Armstrong, Elizabeth L. Garrett-Mayer, and Mario Eisenberger
J Natl Cancer Inst 2008 100: 681-682. [Extract] [Full Text] [PDF]